Compare HMR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMR | IBIO |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | Greece | United States |
| Employees | 52 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 72.2M |
| IPO Year | N/A | 2009 |
| Metric | HMR | IBIO |
|---|---|---|
| Price | $1.51 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $4.75 |
| AVG Volume (30 Days) | 154.7K | ★ 888.9K |
| Earning Date | 06-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $64.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $0.56 |
| 52 Week High | $2.15 | $3.82 |
| Indicator | HMR | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 82.05 | 54.58 |
| Support Level | $0.81 | $1.70 |
| Resistance Level | $1.55 | $2.29 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 91.72 | 74.18 |
Heidmar Maritime Holdings Corp is a commercial and technical management company that operates tanker and dry-bulk vessel pools. The group, along with its subsidiaries, operates as a growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. Its lines of business currently include asset management, tanker pooling, commercial and time charters, assisting clients with the buying and selling of ships, and technical management services for individual vessels, which include assistance in technical operations and crewing of the vessel. Its geographic areas are Singapore, the USA, the Marshall Islands, the United Arab Emirates, Germany, Switzerland, and Other.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.